![Samit Govindji Hathi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Samit Govindji Hathi
Oprichter bij Gowrie Laxmico Ltd.
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Govindji Thakershi Hathi | M | 83 |
Laxmi BNS Holdings Ltd.
![]() Laxmi BNS Holdings Ltd. Drugstore ChainsRetail Trade Founded in 2010, Laxmi BNS Holdings Ltd. is a pharmaceutical distribution and British sales company. The company is based in Ruislip, UK.
Gowrie Laxmico Ltd.
![]() Gowrie Laxmico Ltd. Medical DistributorsDistribution Services Gowrie Laxmico Ltd. distributes pharmaceutical products. The company was founded on October 8, 1997 and is headquartered in Middlesex, the United Kingdom.
Laxmico Ltd.
![]() Laxmico Ltd. Medical DistributorsDistribution Services Part of Gowrie Laxmico Ltd., Laxmico is a wholesaler of pharmaceutical products. The company is based in Ruislip, UK. Laxmico was founded in 2009.
Syri Ltd. (United Kingdom)
![]() Syri Ltd. (United Kingdom) Pharmaceuticals: MajorHealth Technology Part of Gowrie Holdings Ltd., Syri Ltd. is a British UK-based company founded in 2010. The company specializes in the development, licensing, manufacture, and marketing of liquid medicines. | 27 jaar |
Alpa Hathi | M | 56 |
Laxmi BNS Holdings Ltd.
![]() Laxmi BNS Holdings Ltd. Drugstore ChainsRetail Trade Founded in 2010, Laxmi BNS Holdings Ltd. is a pharmaceutical distribution and British sales company. The company is based in Ruislip, UK.
Laxmico Ltd.
![]() Laxmico Ltd. Medical DistributorsDistribution Services Part of Gowrie Laxmico Ltd., Laxmico is a wholesaler of pharmaceutical products. The company is based in Ruislip, UK. Laxmico was founded in 2009.
Gowrie Laxmico Ltd.
![]() Gowrie Laxmico Ltd. Medical DistributorsDistribution Services Gowrie Laxmico Ltd. distributes pharmaceutical products. The company was founded on October 8, 1997 and is headquartered in Middlesex, the United Kingdom.
Syri Ltd. (United Kingdom)
![]() Syri Ltd. (United Kingdom) Pharmaceuticals: MajorHealth Technology Part of Gowrie Holdings Ltd., Syri Ltd. is a British UK-based company founded in 2010. The company specializes in the development, licensing, manufacture, and marketing of liquid medicines. | 6 jaar |
Amit Chunilal Nathwani | M | 64 |
Novalgen Ltd.
![]() Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | 5 jaar |
Nilesh Modi | M | 55 |
Novalgen Ltd.
![]() Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | - |
Michael Owen | M | 73 |
Novalgen Ltd.
![]() Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | 1 jaar |
Richard Fagan | M | 63 |
Novalgen Ltd.
![]() Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | - |
Bharat Kumar Hirji Thakrar | M | 67 |
Novalgen Ltd.
![]() Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | - |
Scott Clarke | M | - |
Novalgen Ltd.
![]() Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | 1 jaar |
Seung Suh Hong | M | 66 |
Novalgen Ltd.
![]() Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | 3 jaar |
Brian Silver | M | 55 |
Novalgen Ltd.
![]() Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | - |
Simon Aron Goldman | M | 45 |
Novalgen Ltd.
![]() Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigd Koninkrijk | 11 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Samit Govindji Hathi
- Persoonlijk netwerk